Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 245

1.

Biologics for the treatment of dyslipidemias: a look beyond conventional therapy.

Yoon CH, Watson K.

Ann Pharmacother. 2014 Feb;48(2):238-49. doi: 10.1177/1060028013511425. Epub 2013 Nov 6. Review.

PMID:
24259646
2.
3.
4.

Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.

McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA.

J Am Coll Cardiol. 2012 Jun 19;59(25):2344-53. doi: 10.1016/j.jacc.2012.03.007. Epub 2012 Mar 28.

5.

Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.

Sullivan D, Olsson AG, Scott R, Kim JB, Xue A, Gebski V, Wasserman SM, Stein EA.

JAMA. 2012 Dec 19;308(23):2497-506. doi: 10.1001/jama.2012.25790.

PMID:
23128163
6.

Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia.

Lee P, Hegele RA.

Expert Opin Investig Drugs. 2013 Nov;22(11):1411-23. doi: 10.1517/13543784.2013.822485. Epub 2013 Jul 26. Review.

PMID:
23889692
8.

Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.

Stein EA, Mellis S, Yancopoulos GD, Stahl N, Logan D, Smith WB, Lisbon E, Gutierrez M, Webb C, Wu R, Du Y, Kranz T, Gasparino E, Swergold GD.

N Engl J Med. 2012 Mar 22;366(12):1108-18. doi: 10.1056/NEJMoa1105803.

9.

Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction.

Tavori H, Melone M, Rashid S.

Expert Rev Cardiovasc Ther. 2014 Oct;12(10):1137-44. doi: 10.1586/14779072.2014.954551. Review. Erratum in: Expert Rev Cardiovasc Ther. 2014 Dec;12(12):1491.

PMID:
25244623
11.

PCSK9 antibodies for the treatment of hypercholesterolemia.

Gouni-Berthold I, Berthold HK.

Nutrients. 2014 Dec 1;6(12):5517-33. doi: 10.3390/nu6125517. Review.

12.

Potential of proprotein convertase subtilisin/kexin type 9 based therapeutics.

Stein EA, Swergold GD.

Curr Atheroscler Rep. 2013 Mar;15(3):310. doi: 10.1007/s11883-013-0310-3. Review.

PMID:
23371064
13.

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.

Joseph L, Robinson JG.

Prog Cardiovasc Dis. 2015 Jul-Aug;58(1):19-31. doi: 10.1016/j.pcad.2015.04.004. Epub 2015 May 1. Review.

PMID:
25936907
14.

Emerging low-density lipoprotein therapies: Targeting PCSK9 for low-density lipoprotein reduction.

Davidson MH.

J Clin Lipidol. 2013 May-Jun;7(3 Suppl):S11-5. doi: 10.1016/j.jacl.2013.03.004. Epub 2013 Mar 26.

15.

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study.

Giugliano RP, Desai NR, Kohli P, Rogers WJ, Somaratne R, Huang F, Liu T, Mohanavelu S, Hoffman EB, McDonald ST, Abrahamsen TE, Wasserman SM, Scott R, Sabatine MS; LAPLACE-TIMI 57 Investigators..

Lancet. 2012 Dec 8;380(9858):2007-17. doi: 10.1016/S0140-6736(12)61770-X. Epub 2012 Nov 6.

16.

Update of Clinical Trials of Anti-PCSK9 Antibodies.

Wu NQ, Li S, Li JJ.

Cardiovasc Drugs Ther. 2015 Apr;29(2):159-69. doi: 10.1007/s10557-015-6582-9. Review.

PMID:
25916406
17.

Efficacy and safety profile of evolocumab (AMG145), an injectable inhibitor of the proprotein convertase subtilisin/kexin type 9: the available clinical evidence.

Cicero AF, Tartagni E, Ertek S.

Expert Opin Biol Ther. 2014 Jun;14(6):863-8. doi: 10.1517/14712598.2014.902929. Epub 2014 Mar 24. Review.

PMID:
24661068
18.

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis.

Navarese EP, Kolodziejczak M, Schulze V, Gurbel PA, Tantry U, Lin Y, Brockmeyer M, Kandzari DE, Kubica JM, D'Agostino RB Sr, Kubica J, Volpe M, Agewall S, Kereiakes DJ, Kelm M.

Ann Intern Med. 2015 Jul 7;163(1):40-51. doi: 10.7326/M14-2957. Review.

PMID:
25915661
19.

An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes.

Zhang L, McCabe T, Condra JH, Ni YG, Peterson LB, Wang W, Strack AM, Wang F, Pandit S, Hammond H, Wood D, Lewis D, Rosa R, Mendoza V, Cumiskey AM, Johns DG, Hansen BC, Shen X, Geoghagen N, Jensen K, Zhu L, Wietecha K, Wisniewski D, Huang L, Zhao JZ, Ernst R, Hampton R, Haytko P, Ansbro F, Chilewski S, Chin J, Mitnaul LJ, Pellacani A, Sparrow CP, An Z, Strohl W, Hubbard B, Plump AS, Blom D, Sitlani A.

Int J Biol Sci. 2012;8(3):310-27. doi: 10.7150/ijbs.3524. Epub 2012 Feb 9.

20.

PCSK9 inhibitors.

Farnier M.

Curr Opin Lipidol. 2013 Jun;24(3):251-8. doi: 10.1097/MOL.0b013e3283613a3d. Review.

PMID:
23652470

Supplemental Content

Support Center